News

Public · Published

RBC Capital maintains Jazz Pharmaceuticals at Outperform, raises price target to $305 from $296

RBC Capital kept its Outperform rating on Jazz Pharmaceuticals and raised its price target to $305 from $296, a 3.0% increase. The new target implies 42.2% upside from the November 2 close of $214.44.

Published:

Updated:

What happened

RBC Capital kept its Outperform rating on Jazz Pharmaceuticals and raised its price target to $305 from $296, a 3.0% increase. The new target implies 42.2% upside from the November 2 close of $214.44.

Confirmed

Global impact / market context

A higher target signals RBC expects more value from Jazz shares. That can support investor confidence and buying interest, and because the target sits well above the recent close, it frames the stock as undervalued and may push other analysts to revisit their own targets.

Analyst inference

Recent analyst notes on Jazz show targets from $275 to $314, with several firms keeping buy-style ratings. That clustering suggests broad positive views, so RBC's modest increase fits an existing upbeat trend rather than a sudden shift in expectations.

Analyst inference

What to watch

  1. Watch whether Jazz Pharmaceuticals shares move toward RBC's $305 target or stay near the November 2 close of $214.44. Confirmed
  2. Track any further analyst rating or price target changes on Jazz to see if the recent run of positive views continues. Proposed
  3. A higher share price would lift Jazz's market value, which means its cost of raising money through new stock sales could fall, changing how it funds research spending. Analyst inference

Evidence

  • Original source link unavailable